Rapid Development of Human Neutralizing Monoclonal Antibodies for SARS-CoV-2
Antibody
Research Institution
Vanderbilt Vaccine Center
Description
We are rapidly developing human neutralizing monoclonal antibodies for SARS-CoV-2. We need funds or services in kind for manufacture and clinical trials of human monoclonal antibodies. We are less than 6 months from trialing in humans.
This project is in need of additional funding to support ongoing research activities. If you are a public or private funder with an interest in supporting this work, please get in touch.
Partnerships
This project is actively seeking industry partnerships to support its ongoing drug development efforts. If you are from an organisation or company that may be able to provide support and have an interest in partnering with this project, please get in touch.
Expert Advice
This project is seeking expert advice. Typically, projects require expert advice on experimental design, assay development, commercialisation, manufacturing, or regulatory considerations. If you are an expert and are interested in providing support to the project, please get in touch.
Get In Touch
Directly connect with the responsible researchers by sending a message.
Thank you! Your message has been received and will be forwarded to the research team!
Oops! Something went wrong while submitting the form.